Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02547961
Recruitment Status : Withdrawn (Project terminated due to revision of local regulations)
First Posted : September 14, 2015
Last Update Posted : July 16, 2020
Information provided by (Responsible Party):
Fuda Cancer Hospital, Guangzhou

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of HER2-CAR-T cell Infusion for advanced HER2 positive breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: HER-2-targeting CAR T Cells infusion Phase 1 Phase 2

Detailed Description:
By enrolling patients with advanced HER2 positive breast cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HER2-CAR-T cell infusion for advanced HER2 positive breast cancer.The CAR consists of a HER-2 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and CD28. Autologous T cells will be gene-engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Chimeric Antigen Receptor-Modified T Cells for HER-2 Positive Recurrent and Metastatic Breast Cancer
Actual Study Start Date : September 2015
Actual Primary Completion Date : August 15, 2016
Actual Study Completion Date : August 15, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: HER2-CAR-T
In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
Biological: HER-2-targeting CAR T Cells infusion
HER-2-targeting CAR t cells infusion in breast cancer

No Intervention: No Intervention

Primary Outcome Measures :
  1. Number of participants with Adverse events [ Time Frame: 24weeks ]

Secondary Outcome Measures :
  1. Tumor load [ Time Frame: 24weeks ]
    Tumor load will be quantified with radiology, bone marrow and/or blood

Other Outcome Measures:
  1. Progress free disease (PFS) [ Time Frame: 1 year ]
  2. Overall survival (OS) [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Chemotherapy refractory Her2 positive breast cancer;
  2. Relapsed patients after anti-Her2 using antibody or kinase inhibitor therapy;
  3. Patients must be 18 years of age or older;
  4. Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-2;
  5. Patients must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters:

Absolute neutrophil count greater than 1500/mm3. Platelet count greater than 100,000/mm3. Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).

Total bilirubin < 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m(2).

  • Seronegative for HIV antibody.
  • Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.
  • Patients must be willing to practice birth control during and for four months following treatment.NOTE:women of child-bearing age must have evidence of negative pregnancy test.
  • Patients must be willing to sign an informed consent.

Exclusion Criteria:

  • 1. Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.

    2.Patients with any of the follo wing pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), < 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) < 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.

    3.Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.

    4.Pregnant and/or lactating women will be excluded. 5.Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.

    6.Patients with any type of primary immunodeficiencies will be excluded from the study.

    7.Patients requiring corticosteroids (other than inhaled) will be excluded. 8.Patients with history of T cell tumors will be excluded. 9.Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02547961

Layout table for location information
China, Guangdong
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China, 510000
Sponsors and Collaborators
Fuda Cancer Hospital, Guangzhou
Layout table for investigator information
Study Chair: Lizhi Niu, PhD Fuda Cancer Hospital
Layout table for additonal information
Responsible Party: Fuda Cancer Hospital, Guangzhou Identifier: NCT02547961    
Other Study ID Numbers: Breast Cancer CAR-T 001
First Posted: September 14, 2015    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: July 2020
Keywords provided by Fuda Cancer Hospital, Guangzhou:
breast cancer
CAR-T cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases